Advertisement
BMY vs LLY
Which Stock Would AI Choose? Bristol-Myers Squibb (BMY) vs. Eli Lilly (LLY) Stock Comparison
Key Takeaways
- LLY has delivered stronger year-to-date gains of about 19% compared to BMY's 9.5%, fueled by demand for its obesity treatments.
- BMY offers a higher dividend yield of 4.36%, appealing to income-focused investors, while LLY trades at a premium valuation with a P/E ratio (price-to-earnings ratio) of 37.88 versus BMY's 16.70.
- Both stocks await Q1 2026 earnings on April 30, with BMY facing expected revenue declines from legacy products and LLY poised for growth from Mounjaro and Zepbound.
- Analysts project higher upside for LLY with a $1,202 target versus BMY's $63, reflecting stronger pipeline catalysts in oncology and obesity.
- BMY shows lower volatility with a beta of 0.27, providing relative stability amid sector pressures.
Introduction
Bristol-Myers Squibb (BMY) and Eli Lilly (LLY) represent contrasting profiles within the pharmaceutical sector, with BMY emphasizing dividend stability and a maturing pipeline, and LLY driving growth through blockbuster obesity and oncology drugs. This stock comparison analyzes their recent market positioning, performance metrics, and key drivers in the current environment. Traders seeking momentum may eye LLY's catalysts, while long-term investors could value BMY's yield and valuation. Understanding these dynamics aids in assessing relative performance and sector exposure.
BMY Overview and Recent Performance
Bristol-Myers Squibb (BMY), a global biopharmaceutical leader, focuses on oncology, immunology, and cardiovascular therapies. Trading around $58 recently, the stock has climbed 9.5% year-to-date and 27% over the past year, near its 52-week high of $62.89. Sentiment reflects steady growth in its newer portfolio offsetting declines in legacy drugs amid generic competition. Key influences include an upcoming Q1 earnings report expecting $1.44 EPS (earnings per share) and $10.92 billion in revenue, alongside a robust 4.36% dividend yield. Analysts maintain a buy consensus with a $63 target, supported by pipeline advancements like TYK2 inhibitors, though operational debt and patent cliffs temper gains in recent market activity.
LLY Overview and Recent Performance
Eli Lilly (LLY), renowned for diabetes, obesity, and oncology innovations, has seen its shares hover near $868 amid volatility from peak levels above $1,100. Year-to-date gains stand at 19%, though one-year returns are more modest at 1%, reflecting GLP-1 (glucagon-like peptide-1) drug momentum tempered by market rotations. Recent developments include the $2.3 billion acquisition of Ajax Therapeutics to bolster hematology and a partnership with Profluent on AI-designed genetic medicines. Strong demand for Mounjaro and Zepbound drives optimism ahead of Q1 earnings, with analysts issuing strong buy ratings and a $1,202 target. These catalysts have shifted sentiment positively despite short-term pullbacks in recent weeks.
Trending AI Robots
Tickeron's Trending AI Robots page showcases the platform's top-performing AI trading bots, curated from hundreds available—specifically 25 selected out of 351 total bots that trade thousands of tickers across various strategies. These bots employ diverse trading styles, from short-term scalping to long-term trend following, with performance metrics highlighting win rates often exceeding 60%, average annual returns in the 20-50% range for top performers, and risk-adjusted Sharpe ratios above 1.5 in favorable conditions. Only those demonstrating superior adaptability to current market volatility, such as shifts in biotech sentiment, earn a spot. Explore Trending AI Robots to identify bots suited to your timeframe and risk tolerance.
Head-to-Head Comparison
In business models, BMY balances mature revenue streams with growth assets, offering lower risk via dividends, while LLY prioritizes high-growth GLP-1 and oncology pipelines at elevated valuations. Growth drivers diverge: BMY's immunology expansions contrast LLY's obesity market dominance. Recent momentum favors LLY's YTD edge, but BMY exhibits steadier trends with lower beta. Risk factors include BMY's patent losses versus LLY's supply constraints. Both share sector exposure to regulatory and reimbursement pressures, but market sentiment leans toward LLY's transformative potential amid biotech rallies.
Tickeron AI Verdict
Tickeron's AI currently favors LLY over BMY, citing superior trend consistency in growth portfolios, robust catalysts from obesity and oncology acquisitions, and higher analyst-implied upside. While BMY provides stability and yield, LLY's relative positioning suggests stronger probabilistic outperformance in the near term, barring earnings surprises.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BMY is a Hold and LLY is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BMY’s FA Score shows that 1 FA rating(s) are green whileLLY’s FA Score has 2 green FA rating(s).
- BMY’s FA Score: 1 green, 4 red.
- LLY’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BMY’s TA Score shows that 2 TA indicator(s) are bullish while LLY’s TA Score has 7 bullish TA indicator(s).
- BMY’s TA Score: 2 bullish, 7 bearish.
- LLY’s TA Score: 7 bullish, 3 bearish.
Price Growth
BMY (@Pharmaceuticals: Major) experienced а +0.92% price change this week, while LLY (@Pharmaceuticals: Major) price change was +3.26% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -0.41%. For the same industry, the average monthly price growth was -1.56%, and the average quarterly price growth was +2.83%.
Reported Earning Dates
BMY is expected to report earnings on Jul 30, 2026.
LLY is expected to report earnings on Aug 05, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (-0.41% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
| BMY | LLY | BMY / LLY | |
| Capitalization | 116B | 898B | 13% |
| EBITDA | 15B | 36.2B | 41% |
| Gain YTD | 7.588 | -6.169 | -123% |
| P/E Ratio | 15.90 | 35.76 | 44% |
| Revenue | 48.5B | 72.2B | 67% |
| Total Cash | 10.5B | 5.28B | 199% |
| Total Debt | 46.4B | 43.4B | 107% |
BMY | LLY | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 56 | 9 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 63 Fair valued | 40 Fair valued | |
PROFIT vs RISK RATING 1..100 | 92 | 17 | |
SMR RATING 1..100 | 24 | 13 | |
PRICE GROWTH RATING 1..100 | 50 | 48 | |
P/E GROWTH RATING 1..100 | 54 | 87 | |
SEASONALITY SCORE 1..100 | 50 | 90 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
LLY's Valuation (40) in the Pharmaceuticals Major industry is in the same range as BMY (63). This means that LLY’s stock grew similarly to BMY’s over the last 12 months.
LLY's Profit vs Risk Rating (17) in the Pharmaceuticals Major industry is significantly better than the same rating for BMY (92). This means that LLY’s stock grew significantly faster than BMY’s over the last 12 months.
LLY's SMR Rating (13) in the Pharmaceuticals Major industry is in the same range as BMY (24). This means that LLY’s stock grew similarly to BMY’s over the last 12 months.
LLY's Price Growth Rating (48) in the Pharmaceuticals Major industry is in the same range as BMY (50). This means that LLY’s stock grew similarly to BMY’s over the last 12 months.
BMY's P/E Growth Rating (54) in the Pharmaceuticals Major industry is somewhat better than the same rating for LLY (87). This means that BMY’s stock grew somewhat faster than LLY’s over the last 12 months.
| BMY | LLY | |
|---|---|---|
| RSI ODDS (%) | N/A | 2 days ago 75% |
| Stochastic ODDS (%) | 2 days ago 58% | 2 days ago 53% |
| Momentum ODDS (%) | 2 days ago 54% | 2 days ago 60% |
| MACD ODDS (%) | 2 days ago 44% | 2 days ago 66% |
| TrendWeek ODDS (%) | 2 days ago 52% | 2 days ago 70% |
| TrendMonth ODDS (%) | 2 days ago 56% | 2 days ago 68% |
| Advances ODDS (%) | 29 days ago 54% | 3 days ago 70% |
| Declines ODDS (%) | 5 days ago 53% | 8 days ago 56% |
| BollingerBands ODDS (%) | 2 days ago 51% | 2 days ago 65% |
| Aroon ODDS (%) | 2 days ago 54% | 2 days ago 60% |
Advertisement
BMY and
Correlation & Price change
A.I.dvisor indicates that over the last year, BMY has been loosely correlated with PFE. These tickers have moved in lockstep 61% of the time. This A.I.-generated data suggests there is some statistical probability that if BMY jumps, then PFE could also see price increases.
| Ticker / NAME | Correlation To BMY | 1D Price Change % | ||
|---|---|---|---|---|
| BMY | 100% | +0.67% | ||
| PFE - BMY | 61% Loosely correlated | -0.81% | ||
| AMGN - BMY | 58% Loosely correlated | -0.07% | ||
| ABBV - BMY | 55% Loosely correlated | +1.09% | ||
| BIIB - BMY | 54% Loosely correlated | -6.43% | ||
| MRK - BMY | 54% Loosely correlated | -0.04% | ||
More | ||||